Phenytoin | Levetiracetam | |
---|---|---|
Easy to administera | ☒ | ☑ |
Rapid onset of actiona | ☑ | ☑ |
Intermediate to long actiona | ☑ | ☑ |
Broad spectruma | ☒ | ☑ |
Minimal morbiditya | ☒ | ☑ |
Useful as maintenance AEDa | ☑ | ☑ |
IV solution compatibilitya | ☒ | ☑ |
Rate of infusion | 20 min (minimum) | 5 min (minimum) |
Effectiveness in CSE (seizure termination rate) | 50–60% | 75–100% |
Evidence base | ||
Cost | ||
Interactions with other drugs | ||
Adverse effects | ||
Potentially fatal | Cardiac arrhythmia Cardiac asystole Stevens-Johnson syndrome | |
Non-fatal | Hypotension Hepatotoxicity Phlebitis Severe extravasation injury (‘purple glove syndrome’) | Dizziness Somnolence Headache Agitation IV site irritation |